Evidence map›Paper›PMID 27533040›Full record

ArticleNature2016

Tumour hypoxia causes DNA hypermethylation by reducing TET activity.

Bernard Thienpont, Jessica Steinbacher, Hui Zhao, Flora D'Anna, Anna Kuchnio, Athanasios Ploumakis, Bart Ghesquière, Laurien Van Dyck, Bram Boeckx, Luc Schoonjans and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Nature, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 347 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
347citing papers in PubMed, 1 pooled it
36.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

347 citing papers in PubMed, 1 synthesis or guideline pooled it, 656 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

287 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 4 countries.

Bernard Thienpont *Vesalius Research Center, VIB, Leuven, Belgium.
Jessica Steinbacher *Department für Chemie und Pharmazie, Ludwig-Maximilians-Universität, München, Germany.
Hui Zhao *Vesalius Research Center, VIB, Leuven, Belgium.
Flora D'Anna *Vesalius Research Center, VIB, Leuven, Belgium.
Anna KuchnioVesalius Research Center, VIB, Leuven, Belgium.
Athanasios PloumakisInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Bart GhesquièreVesalius Research Center, VIB, Leuven, Belgium.
Laurien Van DyckVesalius Research Center, VIB, Leuven, Belgium.
Bram BoeckxVesalius Research Center, VIB, Leuven, Belgium.
Luc SchoonjansVesalius Research Center, VIB, Leuven, Belgium.
Els HermansGynecologic Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.
Frederic AmantGynecologic Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.
Vessela N KristensenDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Kian Peng KohDepartment of Development and Regeneration, and Stem Cell Institute Leuven, KU Leuven, Leuven, Belgium.
Massimiliano MazzoneVesalius Research Center, VIB, Leuven, Belgium.
Mathew ColemanInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Thomas CarellDepartment für Chemie und Pharmazie, Ludwig-Maximilians-Universität, München, Germany.
Peter CarmelietVesalius Research Center, VIB, Leuven, Belgium.
Diether LambrechtsVesalius Research Center, VIB, Leuven, Belgium.
KU Leuven · BECenter for Integrated Protein Science Munich · DEUniversity of Birmingham · GBOslo University Hospital · NOVIB-KU Leuven Center for Cancer Biology · BE

Funding

European Research Council 617595Medical Research Council MR/N021053/1
6 · The paper itself

Abstract

Hypermethylation of the promoters of tumour suppressor genes represses transcription of these genes, conferring growth advantages to cancer cells. How these changes arise is poorly understood. Here we show that the activity of oxygen-dependent ten-eleven translocation (TET) enzymes is reduced by tumour hypoxia in human and mouse cells. TET enzymes catalyse DNA demethylation through 5-methylcytosine oxidation. This reduction in activity occurs independently of hypoxia-associated alterations in TET expression, proliferation, metabolism, hypoxia-inducible factor activity or reactive oxygen species, and depends directly on oxygen shortage. Hypoxia-induced loss of TET activity increases hypermethylation at gene promoters in vitro. In patients, tumour suppressor gene promoters are markedly more methylated in hypoxic tumour tissue, independent of proliferation, stromal cell infiltration and tumour characteristics. Our data suggest that up to half of hypermethylation events are due to hypoxia, with these events conferring a selective advantage. Accordingly, increased hypoxia in mouse breast tumours increases hypermethylation, while restoration of tumour oxygenation abrogates this effect. Tumour hypoxia therefore acts as a novel regulator of DNA methylation.

Indexed as

DNA Methylation5-MethylcytosineAnimalsCell ProliferationDioxygenasesDNA-Binding ProteinsFemaleGene SilencingGenes, Tumor SuppressorHumansMaleMammary Neoplasms, AnimalMiceMixed Function OxygenasesOxidation-ReductionOxygen5-MethylcytosineDioxygenasesDNA-Binding ProteinsMixed Function OxygenasesOxygenProto-Oncogene ProteinsTET1 protein, humanTet2 protein, mouse

Identifiers

PMID27533040
PMCPMC5133388
OpenAlexW2517374546

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.